Conclusions
SURGICAL COMPLICATIONS
The results of our analysis show that the combination of socazolimab with nab-paclitaxel and cisplatin achieved promising MPR and pCR rates and considerable T-stage downstaging with no concomitant increase in surgical complications, demonstrating the effectiveness and safety of this therapy for treating locally advanced ESCC. Based on these outcomes, we anticipate that combined PD-L1 inhibitor treatment and chemotherapy followed by minimally invasive esophagectomy will become an essential neoadjuvant treatment for locally advanced ESCC.